litlas
Log inCreate account

Peter A. Kaufman

Active 1978–2024

67
Papers
18,064
Citations
48
h-index
66
i10-index

Citations

Citations per year for Peter A. Kaufman1974: 1 citations1981: 3 citations1982: 1 citations1987: 1 citations1991: 2 citations1992: 1 citations1993: 2 citations1996: 1 citations1997: 10 citations1998: 5 citations1999: 5 citations2000: 10 citations2001: 6 citations2002: 5 citations2003: 6 citations2004: 4 citations2005: 17 citations2006: 81 citations2007: 126 citations2008: 152 citations2009: 147 citations2010: 156 citations2011: 167 citations2012: 167 citations2013: 172 citations2014: 168 citations2015: 168 citations2016: 144 citations2017: 137 citations2018: 158 citations2019: 412 citations2020: 576 citations2021: 514 citations2022: 446 citations2023: 374 citations2024: 513 citations2025: 281 citations2026: 11 citations1975–1980: no citations, so these years are not shown1983–1986: no citations, so these years are not shown1988–1990: no citations, so these years are not shown1994–1995: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,150 citing papers, 26.6% of this breakdownChina: 572 citing papers, 7.1% of this breakdownItaly: 504 citing papers, 6.2% of this breakdownUnited Kingdom: 458 citing papers, 5.7% of this breakdownGermany: 424 citing papers, 5.3% of this breakdownCanada: 328 citing papers, 4.1% of this breakdownFrance: 319 citing papers, 3.9% of this breakdownSpain: 306 citing papers, 3.8% of this breakdownJapan: 224 citing papers, 2.8% of this breakdownBelgium: 214 citing papers, 2.6% of this breakdownSouth Korea: 208 citing papers, 2.6% of this breakdownAustralia: 207 citing papers, 2.6% of this breakdown
0%26.6%Other 26.7%

Institutions

Fields

  • Medicine68.1%
  • Biochemistry, Genetics and Molecular Biology17.7%
  • Engineering3.5%
  • Business, Management and Accounting3.3%
  • Computer Science1.5%
  • Immunology and Microbiology1.4%
  • Other4.5%

Topics

  • HER2/EGFR in Cancer Research11.7%
  • Advanced Breast Cancer Therapies9.4%
  • Breast Cancer Treatment Studies7.7%
  • Cancer Treatment and Pharmacology4%
  • Monoclonal and Polyclonal Antibodies Research3.3%
  • Cancer-related Molecular Pathways3.2%
  • Other60.7%

Coauthors

All papers

Open in search
  1. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

    Authors: George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, Martin Frenzel, Yong Lin, Susana Barriga, Ian C. P. Smith, Nawel Bourayou, Antonio Llombart‐Cussac - Journal of Clinical Oncology 2017 cited by 1,656

  2. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

    Authors: George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, PierFranco Conte, Yi Lu, Susana Barriga, Karla Hurt, Martin Frenzel, Stephen Johnston, Antonio Llombart‐Cussac - JAMA Oncology 2019 cited by 987

  3. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

    Authors: Edward H. Romond, Edith A. Perez, John Bryant, Vera J. Suman, Charles E. Geyer, Nancy E. Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A. Kaufman, Sandra M. Swain, Thomas M. Pisansky, Louis Fehrenbacher, Leila A. Kutteh, Victor G. Vogel, Daniel W. Visscher, Greg Yothers, Robert B. Jenkins, Ann Brown, Shaker R. Dakhil, Eleftherios P. Mamounas, Wilma L. Lingle, Pamela Klein, James N. Ingle, Norman Wolmark - New England Journal of Medicine 2005 cited by 5,353

  4. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Authors: Nadia Harbeck, Priya Rastogi, Miguel Martín, Sara M. Tolaney, Zhimin Shao, Peter A. Fasching, Chiun‐Sheng Huang, Georgina Garnica Jaliffe, A. Tryakin, Matthew P. Goetz, Hope S. Rugo, Elżbieta Senkus, Laura Testa, Mariette Andersson, Kenji Tamura, Lucia Del Mastro, Guenther G. Steger, Hans Kreipe, Roberto Hegg, Joohyuk Sohn, Valentina Guarneri, Javier Cortés, E.P. Hamilton, Valérie André, Ran Wei, Susana Barriga, S. Sherwood, Tammy Forrester, Montserrat Muñoz-Mateu, Ashwin Shahir, Belén San Antonio, Sarah C. Nabinger, Masakazu Toi, Stephen Johnston, Joyce O’Shaughnessy, M.M. Jimenez, Stephen Johnston, F. Boyle, Guenther G. Steger, Patrick Neven, Zefei Jiang, Mario Campone, Jens Huober, Chikako Shimizu, I. Cicin, Andrew Wardley, Sara M. Tolaney, Gonzalo Gómez Abuin, J. J. Zarba, Elgene Lim, P. Sant, Naishun Liao, Bo Christiansen, Natalja Eigėlienė, J. Martin-Babau, Johannes Ettl, D. Mavroudis, Joanne Chiu, Katalin Boér, R. Nagarkar, Shani Paluch–Shimon, Luca Moscetti, Yoshiatsu Sagara, S.-B. Kim, Rui M. B. Maciel, Vivianne C. G. Tjan‐Heijnen, Reuben Broom, Aleksandra Łacko, M. Schenker, Nikita Volkov, Yoon Sim Yap, M.A. Coccia-Portugal, J. Ángel García Sáenz, Anne Andersson, Tai-Jong Chao, Erhan Gökmen, Hakan Harputluoğlu, O. Berzoy, Debra A. Patt, Heather L. McArthur, Helen K. Chew, Pavani Chalasani, Peter A. Kaufman, Karen L. Tedesco, Stephanie L. Graff - Annals of Oncology 2021 cited by 378

  5. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

    Authors: Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, Javier Cortés, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N. Schwartz, Timothy Pluard, Francesco Ricci, William R. Gwin, Christelle Lévy, Ursa Brown‐Glaberman, Jean-­Marc Ferrero, Maaike de Boer, Sung‐Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik Jakobsen, Einav Nili Gal‐Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar, on behalf of the SOPHIA Study Group - Journal of Clinical Oncology 2022 cited by 80

  6. AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

    Authors: Sara M. Tolaney, Arlene Chan, Katarína Petráková, Suzette Delaloge, Mario Campone, Hiroji Iwata, Parvin F. Peddi, Peter A. Kaufman, Elisabeth De Kermadec, Qianying Liu, Patrick Cohen, Gautier Paux, Lei Wang, Nils Ternès, Eric Boitier, Seock‐Ah Im - Journal of Clinical Oncology 2023 cited by 74

  7. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

    Authors: Roisín M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown‐Glaberman, Jennifer S. Winn, Bryan A. Faller, Adedayo A. Onitilo, Mark E. Burkard, G. Thomas Budd, Ellis Levine, Melanie Royce, Peter A. Kaufman, Alexandra Thomas, Jane B. Trepel, Antonio C. Wolff, Joseph A. Sparano - Journal of Clinical Oncology 2021 cited by 119

  8. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

    Authors: Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L. Graff, Kyong Hwa Park, Rinath Jeselsohn, Umut Demırcı, Miguel Martín, Rachel M. Layman, Sara A. Hurvitz, Sarah Sammons, Peter A. Kaufman, Montserrat Muñoz-Mateu, Ling‐Ming Tseng, Holly Knoderer, Bastien Nguyen, Yanhong Zhou, Elizabeth E. Ravenberg, Lacey M. Litchfield, Seth A. Wander - Journal of Clinical Oncology 2024 cited by 75

  9. Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

    Authors: Sara M. Tolaney, Kevin Kalinsky, Virginia Kaklamani, David R. D’Adamo, Gursel Aktan, Michaela L. Tsai, Ruth O’Regan, Peter A. Kaufman, Sharon Wilks, Eleni Andreopoulou, Debra A. Patt, Yuan Yuan, Grace Wang, Claudio Savulsky, Dongyuan Xing, Ella Kleynerman, Vassiliki Karantza, Sami Diab - Clinical Cancer Research 2021 cited by 136

  10. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

    Authors: Sònia Pernas, Miguel Martín, Peter A. Kaufman, Marta Gil-Martín, P. Gómez Pardo, Sara López‐Tarruella, Luís Manso, Eva Ciruelos, José Alejandro Pérez Fidalgo, Cristina Hernándo, Foluso O. Ademuyiwa, Katherine N. Weilbaecher, Ingrid A. Mayer, Timothy Pluard, Maria Martinez‐García, Linda T. Vahdat, José Manuel Pérez-García, Achim Wach, Debra Barker, Samson Fung, Bárbara Romagnoli, Javier Cortés - The Lancet Oncology 2018 cited by 137

  11. Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

    Authors: Matthew P. Goetz, Erika Hamilton, Mario Campone, Sara A. Hurvitz, Javier Cortés, Stephen Johnston, Antonio Llombart‐Cussac, Peter A. Kaufman, Masakazu Toi, Guy Jérusalem, Hillary Graham, Hong Wang, Valerie M. Jansen, Lacey M. Litchfield, Miguel Martín - Clinical Cancer Research 2023 cited by 41

  12. Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

    Authors: Peter A. Kaufman, Ahmad Awada, Chris Twelves, Louise Yelle, Edith A. Perez, Galina Velikova, Martin Olivo, Yi He, Corina E. Dutcus, Javier Cortés - Journal of Clinical Oncology 2015 cited by 464

  13. Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

    Authors: Adam Brufsky, Musa Mayer, Hope S. Rugo, Peter A. Kaufman, Elizabeth Tan-Chiu, Debu Tripathy, Iulia Cristina Tudor, Lisa I. Wang, Melissa Brammer, Mona Shing, Marianne Ulcickas Yood, Denise A. Yardley - Clinical Cancer Research 2011 cited by 400

  14. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study

    Authors: Komal Jhaveri, Elgene Lim, Rinath Jeselsohn, X. Cynthia, Erika Hamilton, Cynthia R. Osborne, Manali Ajay Bhave, Peter A. Kaufman, J. Thaddeus Beck, Luís Manso, Ritesh Parajuli, Hwei-Chung Wang, Jessica J. Tao, Seock‐Ah Im, Kathleen Harnden, Kan Yonemori, Ajay Dhakal, Patrick Neven, Philippe Aftimos, Jean‐Yves Pierga, Yen‐Shen Lu, Timothy Larson, Yolanda Jerez, Kostandinos Sideras, Joohyuk Sohn, Sung‐Bae Kim, Cristina Saura, Aditya Bardia, Sarah Sammons, Francesca Bacchion, Yujia Li, Eunice Yuen, Shawn T. Estrem, Vanessa Rodrik-Outmezguine, Bastien Nguyen, Roohi Ismail‐Khan, Lillian M. Smyth, Muralidhar Beeram - Journal of Clinical Oncology 2024 cited by 38

  15. Enhancing global access to cancer medicines

    Authors: Javier Cortés, José Manuel Pérez-García, Antonio Llombart‐Cussac, Giuseppe Curigliano, Nagi S. El Saghir, Fátima Cardoso, Carlos H. Barrios, S. M. S. Wagle, Javier Pareja Román, Nadia Harbeck, Alexandru Eniu, Peter A. Kaufman, Josep Tabernero, Laura García‐Estévez, Peter Schmid, Joaquı́n Arribas - CA A Cancer Journal for Clinicians 2020 cited by 205

  16. Fast 3-D Tomographic Microwave Imaging for Breast Cancer Detection

    Authors: Tomasz M. Grzegorczyk, Paul M. Meaney, Peter A. Kaufman, Roberta M. di Florio-Alexander, Keith D. Paulsen - IEEE Transactions on Medical Imaging, IEEE Trans. Medical Imaging 2012 cited by 339

  17. Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

    Authors: Sara A. Hurvitz, Joyce O’Shaughnessy, Ginny Mason, Denise A. Yardley, Mohammad Jahanzeb, Adam Brufsky, Hope S. Rugo, Sandra M. Swain, Peter A. Kaufman, Debu Tripathy, Laura Chu, Haocheng Li, Vincent Antao, Melody Cobleigh - Clinical Cancer Research 2018 cited by 114

  18. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

    Authors: Debu Tripathy, Adam Brufsky, Melody Cobleigh, Mohammad Jahanzeb, Peter A. Kaufman, Ginny Mason, Joyce O’Shaughnessy, Hope S. Rugo, Sandra M. Swain, Denise A. Yardley, Laura Chu, Haocheng Li, Vincent Antao, Sara A. Hurvitz - The Oncologist 2019 cited by 68

  19. Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve

    Authors: Tim A. Ahles, Andrew J. Saykin, Brenna C. McDonald, Yuelin Li, Charlotte T. Furstenberg, Brett Hanscom, Tamsin J. Mulrooney, Gary N. Schwartz, Peter A. Kaufman - Journal of Clinical Oncology 2010 cited by 534

  20. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial

    Authors: Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton, Stephanie L. Graff, Kyong Hwa Park, Rinath Jeselsohn, Umut Demirci, Miguel Martín, Rachel M. Layman, Sara A. Hurvitz, Sarah Sammons, Peter A. Kaufman, Montserrat Muñoz-Mateu, Jiun‐I Lai, Holly Knoderer, Cynthia Sandoval, Aarti Chawla, Bastien Nguyen, Yanhong Zhou, Elizabeth E. Ravenberg, Lacey M. Litchfield, Lillian M. Smyth, Seth A. Wander - Journal of Clinical Oncology 2024 cited by 63

  21. A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.

    Authors: Komal Jhaveri, Rinath Jeselsohn, Elgene Lim, Erika Hamilton, Kan Yonemori, J. Thaddeus Beck, Peter A. Kaufman, Sarah Sammons, Manali Bhave, Cristina Saura, Emiliano Calvo, Tarek Meniawy, Timothy Larson, X. Cynthia, Javier García-Corbacho, Shanshan Cao, Shawn T. Estrem, Jennifer L. Milata, Bastien Nguyen, Muralidhar Beeram - Journal of Clinical Oncology 2022 cited by 39

  22. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

    Authors: Edith A. Perez, Edward H. Romond, Vera J. Suman, Jong‐Hyeon Jeong, Nancy E. Davidson, Charles E. Geyer, Silvana Martino, Eleftherios P. Mamounas, Peter A. Kaufman, Norman Wolmark - Journal of Clinical Oncology 2011 cited by 718

  23. Cognitive function in breast cancer patients prior to adjuvant treatment

    Authors: Tim A. Ahles, Andrew J. Saykin, Brenna C. McDonald, Charlotte T. Furstenberg, Bernard F. Cole, Brett Hanscom, Tamsin J. Mulrooney, Gary N. Schwartz, Peter A. Kaufman - Breast Cancer Research and Treatment 2007 cited by 346

  24. Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy

    Authors: Peter A. Kaufman, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva‐Maria Grischke, Valérie André, C. Stoffregen, Sarah Shekarriz, Gregory L. Price, Gebra Cuyún Carter, George W. Sledge - The Oncologist 2019 cited by 83